Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations

Lucia Mora-Jimenez, Miguel Valencia, Rocio Sanchez-Carpintero, Jan Tønnesen, Saja Fadila, Moran Rubinstein, Manuela Gonzalez-Aparicio, Maria Bunuales, Eva Fernandez-Pierola, Maria Jesus Nicolas, Elena Puerta, Cristina Miguelez, Paula Gimenez Minguez, Sara Lumbreras, Gloria Gonzalez-Aseguinolaza, Ana Ricobaraza*, Ruben Hernandez-Alcoceba*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Dravet syndrome is a genetic encephalopathy characterized by severe epilepsy combined with motor, cognitive, and behavioral abnormalities. Current antiepileptic drugs achieve only partial control of seizures and provide little benefit on the patient's neurological development. In >80% of cases, the disease is caused by haploinsufficiency of the SCN1A gene, which encodes the alpha subunit of the Nav1.1 voltage-gated sodium channel. Novel therapies aim to restore SCN1A expression in order to address all disease manifestations. We provide evidence that a high-capacity adenoviral vector harboring the 6-kb SCN1A cDNA is feasible and able to express functional Nav1.1 in neurons. In vivo, the best biodistribution was observed after intracerebral injection in basal ganglia, cerebellum, and prefrontal cortex. SCN1A A1783V knockin mice received the vector at 5 weeks of age, when most neurological alterations were present. Animals were protected from sudden death, and the epileptic phenotype was attenuated. Improvement of motor performance and interaction with the environment was observed. In contrast, hyperactivity persisted, and the impact on cognitive tests was variable (success in novel object recognition and failure in Morris water maze tests). These results provide proof of concept for gene supplementation in Dravet syndrome and indicate new directions for improvement.

Original languageEnglish
Pages (from-to)585-602
Number of pages18
JournalMolecular Therapy Nucleic Acids
StatePublished - 3 Sep 2021


FundersFunder number
ERA-NeT E-RareAC17/00029
Inocente-inocente Foundation
Chartered Institute of Management Accountants
Universidad de Navarra
Instituto de Salud Carlos III


    • Dravet syndrome
    • Nav1.1.
    • SCN1A
    • adenovirus
    • encephalopathy
    • epilepsy
    • gene therapy


    Dive into the research topics of 'Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations'. Together they form a unique fingerprint.

    Cite this